Akums Drugs & Pharmaceuticals Ltd

On 24-Nov, Akums Drugs & Pharmaceuticals Ltd witnessed a notable decline in its share price, closing at ₹414.30, down ₹7.35 or 1.74%. This drop reflects a continuation of a downward trend influenced by weak financial performance, falling investor participation, and underwhelming market returns compared to benchmarks.

Akums Drugs has shown significant recovery and growth, with net sales reaching 4,118.16 crore in March 2025, up from 3,654.82 crore in March 2023, and a profit after tax of 343.78 crore, recovering from a loss the previous year. The company's financial position is stable, with improved cash flow and earnings per share increasing to 22.09.

Akums Drugs experienced significant fluctuations in financial performance over the past three years, with a notable recovery in FY 2025, reporting net sales of 4,118.16 crore and a profit after tax of 343.78 crore, up from a loss the previous year. Key improvements included a rise in operating profit to 516.61 crore and a substantial increase in earnings per share to 22.09.

As of 10-Nov, Akums Drugs & Pharmaceuticals Ltd's stock price is Rs 439.70, down 3.25%, and has declined 6.63% over the last three days. The stock has underperformed significantly over the past year, with a return of -44.83%, amid disappointing financial results and reduced institutional investor participation.

As of 20-Oct, Akums Drugs & Pharmaceuticals Ltd is currently priced at 467.40, reflecting a short-term gain despite a significant year-long decline of -48.58%. The stock's recent uptick contrasts with ongoing financial challenges and poor long-term growth metrics.

As of October 10, 2025, Akums Drugs shows a mildly bearish trend due to bearish weekly MACD and KST, despite bullish weekly and monthly RSI readings indicating some underlying strength.

As of October 10, 2025, the market trend is mildly bearish, indicated by bearish weekly MACD and KST indicators, despite some bullish signals from the RSI, suggesting underlying strength.

As of October 10, 2025, the trend is mildly bearish due to bearish signals from the weekly MACD and KST indicators, despite some bullish momentum in the RSI readings.

As of October 7, 2025, the technical trend is bearish with moderate strength, driven by bearish MACD, moving averages, and Bollinger Bands, while showing divergence with a bullish monthly RSI and significant underperformance against the Sensex.

As of October 6, 2025, the market trend is mildly bearish, indicated by bearish weekly MACD and KST indicators, daily moving averages, and recent price action, despite a bullish monthly RSI and Dow Theory reflecting a similar sentiment.

As of 29-Sep, Akums Drugs & Pharmaceuticals Ltd is facing a stock price decline to 444.00, down 2.35 (-0.53%), and has fallen for six consecutive days, totaling a 6.84% drop. The stock is trading below all moving averages and has underperformed significantly over the past year, with a return of -46.81%, amid operational challenges and disappointing quarterly results.

As of 24-Sep, Akums Drugs & Pharmaceuticals Ltd's stock price is 465.00, down 1.19%, and has seen a significant decline of 44.77% over the past year despite a 1362% increase in profits. The company faces challenges with low long-term growth and has underperformed against its sector and the broader market.

As of 23-Sep, Akums Drugs & Pharmaceuticals Ltd is priced at 470.95, down 1.11% and has underperformed with a 45.04% decline over the past year. Despite low debt and attractive valuation, the company faces poor long-term growth and negative investor sentiment due to declining profits and flat results.

As of 22-Sep, Akums Drugs & Pharmaceuticals Ltd's stock price is declining at 474.10, down 0.52%, following a trend reversal after two days of gains. Despite short-term outperformance against the Sensex, the stock has significantly underperformed over the past year and shows poor long-term growth prospects, compounded by declining investor interest.